Regulatory & PolicyThe National Institutes of Health (NIH) has been a cornerstone of biomedical research innovation and public health advancement. However, recent resignations by four senior leaders spotlight serious concerns over editorial interference and censorship, raising questions about the organization's commitment to scientific rigor and transparency. This development underscores a growing apprehension within the biomedical community regarding governance and autonomy at one of the world's premier research institutions.
TCB Team·Jan 11, 2026
Healthcare InvestmentWith participation from prominent investors including Andreessen Horowitz and Atomico, Pomelo plans to leverage the funding to expand its care models and technologies beyond maternity services, potentially impacting women’s health more broadly.
TCB Team·Jan 10, 2026 
Medical TechnologyThe funding enables Apella to accelerate development and deployment of its AI platform for hospitals. Its technology aims to optimize operating room scheduling and utilization, enhancing patient access and improving clinician work conditions.
TCB Team·Jan 10, 2026 
Biotech InnovationAktis Oncology’s public offering is set to strengthen its position in the radiopharmaceutical sector. The company’s novel approach with miniprotein-based radioconjugates promises potential benefits over existing targeted radiation therapies. Additionally, Aktis has established a discovery partnership with Eli Lilly to enhance its pipeline.
TCB Team·Jan 10, 2026 
Biotech InnovationIllumina named former NIH genomics director Eric Green as its Chief Medical Officer. His appointment comes as the company continues to push boundaries in genomics technologies and applications. Green’s experience is expected to enhance clinical strategy and innovation at Illumina.
TCB Team·Jan 9, 2026 
Biopharmaceutical IndustryInsmed reported that Brinsupri generated $144.6 million in sales in the first full quarter of 2025, surpassing expectations for the treatment of bronchiectasis. This strong initial commercial performance highlights continued demand for innovative therapies in chronic lung conditions.
TCB Team·Jan 9, 2026 
Healthcare InvestmentAktis Oncology’s sizeable IPO reflects growing investor interest in innovative radiopharmaceutical approaches for cancer. The company’s pipeline focuses on miniprotein radioconjugates aimed at targeted radiation delivery, and it benefits from a discovery partnership with Eli Lilly.
TCB Team·Jan 9, 2026 
Biotech InnovationDespite promises of a gene therapy delivery platform avoiding viral vectors, Rampart Bioscience is closing, highlighting ongoing challenges in gene therapy innovation and delivery technologies.
TCB Team·Jan 9, 2026 
Biotech InnovationBuilding on the pioneering work of Baby KJ, this startup leverages both scientific breakthroughs and new FDA regulatory programs to accelerate development of personalized gene therapies utilizing CRISPR technology.
TCB Team·Jan 9, 2026 
Biopharmaceutical IndustryFollowing a late-stage clinical trial failure for Gohibic, an emergency use authorized COVID-19 antibody, InflaRx is restructuring to reduce spending and shift focus within its therapeutic pipeline.
TCB Team·Jan 9, 2026 
Biotech InnovationThe startup’s lead candidate is Phase 2-ready and hits the same dual targets as Amgen’s therapy but may offer better dosing benefits. Their pipeline also positions them against Roche and Novo Nordisk programs in development.
TCB Team·Jan 9, 2026 
Healthcare InvestmentThis potential consolidation could be one of the largest private equity-backed health tech ventures, focusing on integrating payer, provider, and data services. The outcome remains uncertain in terms of value delivery or success.
TCB Team·Jan 9, 2026 